Lancet Oncology, 20, 1273-1285 Lancet oncology, 20(9), 1273-1285. Elsevier Science The Lancet Oncology, 20(9), 1273-1285 PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X The Lancet Oncology Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC Lancet Oncology, 20, 9, pp. 1273-1285
Mandonnet, E, Wager, M, Almairac, F, Baron, M-H, Blonski, M, Freyschlag, C F, Barone, F, Fontaine, D, Pallud, J, Hegi, M, Viegas, C, Zetterling, M, Spena, G, Goodden, J, Rutten, G-J, Taillandier, L, Foroglu, N, Darlix, A, Skrap, M, Martino, J, von Campe, G, Madadaki, C, Gayat, E, de Witt Hamer, P, Robles, S G, Sarubbo, S, Santorius, T, Bello, L, Forster, M-T & Duffau, H 2017, ' Survey on current practice within the European Low-Grade Glioma Network: Where do we stand and what is the next step? ', Neuro-Oncology Practice, vol. 4, no. 4, pp. 241-247 . https://doi.org/10.1093/nop/npw031 Neuro-Oncol.Pract. Neuro-Oncol.Pract., 2017, 4 (4), pp.241-247. ⟨10.1093/nop/npw031⟩ Neuro-Oncology Practice, 4(4), 241-247. Oxford University Press